QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy.
QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy.
复制标题
DOI：
10.1080/13880209.2022.2056206
复制
发表时间：
2022-12
影响因子：
3.8
通讯作者：
Zhang J
中科院分区：
文献类型：
--
作者：
Lv S;Zhang W;Yuan P;Lu C;Dong J;Zhang J
QiShenYiQi pill (QSYQ) is a traditional Chinese medicine with a myocardial protective effect. To explore the effect of QSYQ on myocardial collagen metabolism in rats with autoimmune cardiomyopathy and explore the underlying mechanism from the aspect of apoptosis. We established an autoimmune cardiomyopathy model using Lewis rats. The rats were then randomly divided into six groups (n = 8): control, model, 3-methyladenine (15 mg/kg, intraperitoneal injection), QSYQ low-dose (135 mg/kg, gavage), QSYQ medium dose (270 mg/kg, gavage), and QSYQ high-dose (540 mg/kg, gavage) for four weeks. Van Gieson staining was applied for myocardial pathological characteristics, TUNEL fluorescence for myocardial cell apoptosis, enzyme-linked immunosorbent assay (ELISA) for serum PICP, PIIINP, and CTX-I levels, and western blot analysis for type I/III myocardial collagen, Bcl-2, Bax, and caspase-3 proteins. Results showed that QSYQ (135, 270, or 540 mg/kg) significantly reduced the expression of myocardial type I/III collagen, and concentrations of serum PICP, PIIINP, and CTX-I in rats. Moreover, QSYQ could alleviate myocardial fibrosis more effectively at a higher dose. QSYQ could also inhibit myocardial apoptosis via downregulating Bcl-2 expression, and upregulating Bax and caspase-3 expression levels. The QSYQ can improve myocardial collagen metabolism by inhibiting apoptosis, which provides a potential therapeutic approach for autoimmune cardiomyopathy.
登录
查看更多内容
影响因子：
3.7
作者：
Xie Y;Li M;Wang X;Zhang X;Peng T;Yang Y;Zou Y;Ge J;Chen H;Chen R
通讯作者：
Chen R
DOI：
10.1016/0735-1097(95)00148-s
发表时间：
1995-07-01
影响因子：
24
作者：
GROGAN, M;REDFIELD, MM;RODEHEFFER, RJ
通讯作者：
RODEHEFFER, RJ
影响因子：
--
作者：
Bracamonte-Baran W;Čiháková D
通讯作者：
Čiháková D
DOI：
10.2147/dddt.s82146
发表时间：
2015
期刊：
Drug design, development and therapy
影响因子：
--
作者：
Chen JR;Wei J;Wang LY;Zhu Y;Li L;Olunga MA;Gao XM;Fan GW
通讯作者：
Fan GW
伊伐布雷定预防病毒性心肌炎进展为扩张型心肌病的保护作用
影响因子：
5.6
作者：
Yue-Chun L;Guang-Yi C;Li-Sha G;Chao X;Xinqiao T;Cong L;Xiao-Ya D;Xiangjun Y
通讯作者：
Xiangjun Y